Cover Image
Read Now

Evidence brief: Factors that optimize therapy with repetitive transcranial magnetic stimulation for treatment-resistant depression

Major depressive disorder is one of the most common mental disorders in the general and Veteran populations. The one to two-thirds of MDD patients who do not respond to the first antidepressant prescribed, and the 15% to 33% who do not respond to multiple drugs are defined as having treatment-resist...

Full description

Bibliographic Details
Main Authors: Peterson, Kim, McCleery, Ellen (Author), Waldrip, Kallie (Author)
Corporate Authors: United States Department of Veterans Affairs, Portland VA Medical Center Evidence-based Synthesis Program Center, Quality Enhancement Research Initiative (U.S.)
Format: eBook
Language:English
Published: Washington, DC Department of Veterans Affairs, Health Services Research And Development Service September 2014, 2014
Series:Evidence-based synthesis program
Online Access:
Collection: National Center for Biotechnology Information - Collection details see MPG.ReNa
Description
Summary:Major depressive disorder is one of the most common mental disorders in the general and Veteran populations. The one to two-thirds of MDD patients who do not respond to the first antidepressant prescribed, and the 15% to 33% who do not respond to multiple drugs are defined as having treatment-resistant depression (TRD). Repetitive transcranial magnetic stimulation (rTMS) is one of many possible options for treating TRD. It is supported by two FDA-cleared protocols and acceptable acute efficacy based on a recent Comparative Effectiveness Review conducted by the RTI-UNC EPC. This Evidence Brief synthesizes the literature on factors that optimize rTMS therapy in patients with TRD.
Item Description:At head of title: QUERI.
Physical Description:1 PDF file (ii, 31 pages) illustrations

Similar Items